Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on Most Favored Nation
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies:"For too many years, Americans have subsidized the research…
Learn more
BIO Statement on Industry Tariffs
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented medicines in the US:“We share the Administration’s…
Learn more
BIO Extends Agreement with Avantor for Five…
Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The Biotechnology Innovation Organization (BIO)…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Statement on Senate GOP Tax Reform Proposal
November 10, 2017
Washington, DC (November 10, 2017) – Biotechnology Innovation Organization (BIO) Senior Vice President of Communications Kenneth Lisaius released the following statement regarding the Senate GOP tax reform proposal.
BIO Statement on USDA Withdrawal of 340 Biotech Rules
November 6, 2017
The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology. The…
BIO Releases Plan to Unleash Innovation in Fight against Opioid Abuse and Addiction
November 2, 2017
Washington, DC (November 2, 2017) – The Biotechnology Innovation Organization (BIO) today released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction.Many of BIO’s…
BIO Statement on House GOP Tax Reform Bill
November 2, 2017
Washington, DC (November 2, 2017) – Biotechnology Innovation Organization (BIO) Jim Greenwood released the following statement today regarding the Tax Cuts and Jobs Act:“BIO applauds Chairman Brady and the House Ways & Means Committee for…
BIO Applauds MLP Parity Act, Thanks Senate and House Sponsors
October 25, 2017
The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to…
BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm Bill
October 19, 2017
BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and…
BIO Applauds Senate Introduction of Renewable Chemicals Tax Credit
October 19, 2017
BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short…
BIO Investor Forum Concludes
October 18, 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase…
Hill Leaders Urge Support for Reg System that Supports Ag Innovation
October 17, 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders” Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a…
BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill
October 9, 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today